
HER2-Positive Gastrointestinal Cancers — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Oncology Today with Dr Neil Love
00:00
Choosing HER2 therapy after frontline BTC
Panelists compare trastuzumab combinations, tucatinib, T-DXd and zanidatamab for second-line HER2-positive biliary cancers.
Play episode from 04:38
Transcript


